biotechnology stocks Archives

ive professionals meet around a conference table with laptops and calendars, beside a whiteboard highlighting December EoE data and EPRX.

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. October 27, 2026 304Views 0Likes

With its 120-patient target reached, encouraging early durability data and a November investor calendar, Eupraxia Pharmaceuticals is building a more substantial case for long-acting drug delivery. Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) is approaching the kind of stretch that can move a…

Illustration of traders celebrating on a stock exchange floor beside a display showing Lycia Therapeutics (LYCA) up 67% in its IPO debut.

Lycia Therapeutics Stock Jumps 67% in IPO Debut as Wall Street Backs a New Approach to Allergy Treatment ( $BBC $IBB $LYCA $XBI )

by John F. Heerdink, Jr. October 25, 2026 515Views 0Likes

An upsized $317.5 million offering gives Lycia Therapeutics (NASDAQ: LYCA) fresh capital to pursue protein-degrading medicines, with early human data and 2027 clinical milestones sharpening the investment story. October 24, 2026 Wall Street has found a biotechnology company with an unusually literal…

Illustration of rising oil prices and investors reviewing AI financing costs for the weekly market summary ending October 23, 2026.

Weekly Market Summary, October 23, 2026: Oil Tops $100 as Wall Street Questions AI’s Financing Bill -( $EPRX $MODD $NVDA $SER $SPCX $SKHY $TSLA$MRK $MRNA )

by John F. Heerdink, Jr. October 23, 2026 227736Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Vintage comic-style illustration of a Viking warrior holding a $575 million money bag, symbolizing Viking Therapeutics’ obesity drug development ambitions.

Viking Therapeutics’ $575 Million Raise Gives Its Obesity Ambitions New Muscle -( $VKTX $IBB $XBI )

by John F. Heerdink, Jr. October 20, 2026 352Views 0Likes

With oral VK2735 entering Phase 3 and injectable trials fully enrolled, Viking Therapeutics (NASDAQ: VKTX) is building a broader case in weight management. Viking Therapeutics (NASDAQ: VKTX) has strengthened two foundations of its obesity-drug investment story: the capital to advance its programs…

Illustration of AI stocks rising along a glowing green circuit-board path as houses tumble into a chasm, contrasting the Nasdaq’s 1.11% gain with weak housing confidence on October 19, 2026.

Stock Market Today, October 19, 2026: Nasdaq Gains 1.11% as AI Stocks Rebound, Housing Confidence Weakens -( $AAPL $AMZN $AMWL $DOCS $EPRX $JPM $LPL $MODD $NFLX $NVDA $SER $SLN $SPCX $TSLA $WFC )

by John F. Heerdink, Jr. October 19, 2026 199426Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Futuristic biotech illustration featuring a glowing digital bull, rising market arrows, and research pathways labeled Disc Medicine, Arcutis and Parabilis leading toward a biotechnology innovation hub.

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

by John F. Heerdink, Jr. October 19, 2026 485Views 0Likes

A pivotal trial victory, a growing dermatology franchise and an approaching oncology catalyst put IRON, ARQT and PBLS in the spotlight, while the BBC biotech ETF offers a broader view of the sector. October 19, 2026 Biotechnology investors are being offered three…

Illustration of a circuit-covered Wall Street bull above a market chasm, beneath an AI brain and inflation tornado, with a $2 trillion label.

Weekly Market Summary – October 16, 2026: Nasdaq Falls 4.5% as AI Jitters, Inflation and a $2 Trillion Deficit Test Wall Street -( $EPRX $MODD $NVDA $SER $SPCX $TRV $TSLA )

by John F. Heerdink, Jr. October 16, 2026 181581Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Eupraxia Pharmaceuticals illustration showing a dart hitting a 120-patient enrollment target, a December data calendar, and the EPRX stock ticker.

Eupraxia Pharmaceuticals Hits RESOLVE Enrollment Target as December EoE Data Come Into Focus -( $EPRX $XBI $IBB )

by John F. Heerdink, Jr. October 16, 2026 478Views 0Likes

With 120 patients enrolled in its Phase 2b study, Eupraxia’s drug-delivery platform moves toward a consequential clinical test. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), the story is becoming less about recruiting patients and more about what their results might reveal.…

Vintage comic-style illustration of three bulls pulling a loaded wagon through sunny farmland, with “EPRX” and “Trio of Bulls” above.

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. October 12, 2026 671Views 0Likes

Wall Street Price targets of $16, $17 and $18 seem to underscore the potential for a long-acting treatment as December clinical data approach Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has received a timely vote of confidence from three research firms, with newly…

Alt Text: Illustration of the Nobel Prize in Medicine lighting a new bull market for brain science, featuring a glowing brain, neural connections, a rising stock-market chart and a charging digital bull above a city skyline as researchers look on.

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

by John F. Heerdink, Jr. October 5, 2026 426Views 0Likes

The 2026 Nobel Prize in Physiology or Medicine has put optogenetics, the science of using light to control precisely selected nerve cells, squarely in the global spotlight. For many, the award is more than a ceremonial victory lap for academic neuroscience:…

Tag: biotechnology stocks

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

Lycia Therapeutics Stock Jumps 67% in IPO Debut as Wall Street Backs a New Approach to Allergy Treatment ( $BBC $IBB $LYCA $XBI )

Weekly Market Summary, October 23, 2026: Oil Tops $100 as Wall Street Questions AI’s Financing Bill -( $EPRX $MODD $NVDA $SER $SPCX $SKHY $TSLA$MRK $MRNA )

Viking Therapeutics’ $575 Million Raise Gives Its Obesity Ambitions New Muscle -( $VKTX $IBB $XBI )

Stock Market Today, October 19, 2026: Nasdaq Gains 1.11% as AI Stocks Rebound, Housing Confidence Weakens -( $AAPL $AMZN $AMWL $DOCS $EPRX $JPM $LPL $MODD $NFLX $NVDA $SER $SLN $SPCX $TSLA $WFC )

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

Weekly Market Summary – October 16, 2026: Nasdaq Falls 4.5% as AI Jitters, Inflation and a $2 Trillion Deficit Test Wall Street -( $EPRX $MODD $NVDA $SER $SPCX $TRV $TSLA )

Eupraxia Pharmaceuticals Hits RESOLVE Enrollment Target as December EoE Data Come Into Focus -( $EPRX $XBI $IBB )

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

Your Guide To Staying Informed In The Markets